The 1st episode of 2021 covers 5 FDA updates from December 2020-Pralsetinib for RET-mutated medullary thyroid cancer-The new HER2-targeting margetuximab-Selinexor and the Boston study-Relugolix, an oral GnRH antagonist-Adjuvant osimertinib approved (ADAURA)